GlassScriptPhysician profile
Shaun N Patel
NPI 1891916334
$457,795.87
in general payments reported to CMS, 2019-2025
6 companies · $51K in 2025
The $51K reported for 2025 was more than what 97% of Vascular & Interventional Radiology providers received nationally (typical 2025 total: $537).
See the full distribution for Vascular & Interventional Radiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $63K · 2020: $63K · 2021: $83K · 2022: $72K · 2023: $74K · 2024: $51K · 2025: $51K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $171K · Food and Beverage: $2,908 · Travel and Lodging: $2,040.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $171,375.00 |
| Food and Beverage | $2,908.19 |
| Travel and Lodging | $2,039.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $457,542.40 | 2019-2025 | Dysport, Epsolay, Aklief |
| Revance Therapeutics, INC. | $128.09 | 2025 | Daxxify |
| Stryker Corporation | $62.52 | 2019 | |
| Boston Scientific Corporation | $27.97 | 2023 | Wavewriter Alpha Prime 16 |
| Solta Medical, A Division of Bausch Health US, LLC | $19.19 | 2025 | |
| Allergan, INC. | $15.70 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shaun Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.